Comparative Pharmacology
Head-to-head clinical analysis: HARMONYL versus RAUTENSIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HARMONYL versus RAUTENSIN.
HARMONYL vs RAUTENSIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Harmonyl is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and blood pressure.
Combination of Rauwolfia serpentina alkaloids (e.g., reserpine) that deplete catecholamines and serotonin from peripheral sympathetic nerve endings and brain, reducing total peripheral resistance and cardiac output.
25 mg orally once daily, taken with food. Maximum dose: 50 mg once daily.
1-2 tablets (each containing Rauwolfia serpentina 50 mg and flumethiazide 0.5 mg) orally once daily.
None Documented
None Documented
Terminal half-life: 12–18 hours (mean 15 h); extends to 24–30 h in hepatic impairment
The terminal elimination half-life of rauwolfia alkaloids is approximately 50-100 hours, with a mean of about 72 hours. This long half-life supports once-daily dosing and leads to slow accumulation and sustained antihypertensive effect.
Renal: 70% as unchanged drug; Biliary/fecal: 20% as metabolites; 10% other
Rautensin (rauwolfia alkaloids) is primarily excreted via hepatic metabolism and biliary-fecal elimination, with less than 1% excreted unchanged in urine. Renal excretion accounts for approximately 10% of metabolites, while biliary/fecal elimination accounts for approximately 90%.
Category C
Category C
Antihypertensive
Antihypertensive